Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.64 |
| ▸ | CA1 | P00915 | 3/20 | 0.64 |
| ▸ | CA2 | P00918 | 3/20 | 0.64 |
| ▸ | CA7 | P43166 | 3/20 | 0.64 |
| ▸ | CA9 | Q16790 | 3/20 | 0.64 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | CA3 | P07451 | 2/20 | 0.64 |
| ▸ | CA4 | P22748 | 2/20 | 0.64 |
| ▸ | CA6 | P23280 | 2/20 | 0.64 |
| ▸ | CA5A | P35218 | 2/20 | 0.64 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | SELL | P14151 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9787632 | 0.90 | CA12 (0.73) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10316072 | 0.84 | CA12 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30657986 | 0.84 | CA12 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL26653829 | 0.84 | CA12 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6092664 | 0.84 | CA12 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2684340 | 0.84 | TTR (0.72) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1313079 | 0.84 | TPMT (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29998931 | 0.84 | TTR (0.72) | CA12CA1CA2CA7CA9 | |
| SCHEMBL21837082 | 0.84 | TTR (0.72) | CA12CA1CA2CA7CA9 | |
| SCHEMBL221480 | 0.81 | CES2 (0.67) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111849507-A | Fluorine-containing liquid crystal molecule with cholesterol as chiral center and preparation method thereof | 智谱纳米科技(上海)有限公司 | 2020-10-30 | — | — | CN | claimed |
| US-12497428-B2 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2025-12-16 | — | — | US | disclosed |
| WO-2025224512-A1 | NOVEL COMPOUND AS 17-BETA-HYDROXYSTEROID DEHYDROGENASE 13 (HSD17B13) INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 삼진제약주식회사 | 2025-10-30 | — | — | WO | disclosed |
| EP-4634169-A1 | 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF | Pfizer Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4598908-A1 | HSD17B13 INHIBITORS AND/OR DEGRADERS | Pfizer Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
| WO-2024127297-A1 | 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF | PFIZER INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20240150334-A1 | HSD17B13 INHIBITORS AND/OR DEGRADERS | PFIZER INC. (US) | 2024-05-09 | — | — | US | disclosed |
| US-20060004112-A1 | Molecular chains of the liquid crystalline polymer (e.g. polybenzoxazole, polybenzothiazole, and polybenzimidazole) having an ionic disosciative group and molecular chain orientated in a specific direction; allows permeation of hydrogen ions generated at a fuel electrode (anode) to cathode | POLYMATECH CO., LTD. | 2006-01-05 | — | — | US | disclosed |
| WO-2005080317-A2 | THERAPEUTIC AMIDE DERIVATIVES | PFIZER JAPAN, INC. (JP) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005063385-A1 | METHOD FOR OXIDIZING SATURATED HYDROCARBONS | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2005-07-14 | — | — | WO | disclosed |
| US-20030216577-A1 | Preparation of aromatic and heteroaromatic carboxylic acids by catalytic ozonolysis | DSM FINE CHEMICALS AUSTRIA NFG GMBH & COKG (AT) | 2003-11-20 | — | — | US | disclosed |
| EP-1362840-A1 | Process for the preparation of aromatic and heteroaromatic carboxylic acids via catalytic ozonolysis | DSM Fine Chemicals Austria Nfg GmbH & Co KG (AT) | 2003-11-19 | — | — | EP | disclosed |
| EP-0757028-B1 | Process for the preparation of aromatic carbonic acid esters | CLARIANT GMBH (DE) | 1999-12-29 | — | — | EP | disclosed |
| US-5874608-A | Process for the preparation of esters of aromatic carboxylic acid | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-02-23 | — | — | US | disclosed |
| US-5744628-A | Process for the preparation of esters of aromatic carboxylic acids | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-04-28 | — | — | US | disclosed |
| EP-0811601-A1 | Process for the preparation of aromatic carbonic acid esters | Clariant GmbH (DE) | 1997-12-10 | — | — | EP | disclosed |
| EP-0757028-A1 | Process for the preparation of aromatic carbonic acid esters | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | HSD17B13, HSD17B3, HSD17B1 | CA12 2425/4885CA1 3878/4885CA2 3939/4885 |
| US-20240150334-A1 | HSD17B13 INHIBITORS AND/OR DEGRADERS | HSD17B1, HSD17B3, HSD17B13 | CA12 3053/4885CA1 3741/4885CA2 4080/4885 |
| US-12497428-B2 | Galactoside inhibitor of galectins | LGALS1, LGALS3, LGALS2 | CA12 414/4885CA1 1398/4885CA2 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.